PMID

Data

Article Title

Organization

Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARa Selective Agonist.

Bristol-Myers Squibb

Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPAR¿ agonists.

Glaxosmithkline

Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.

Universit£

Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.

Nippon Shinyaku

Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.

Nippon Shinyaku

Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.

Johnson & Johnson

Conversion of human-selective PPARalpha agonists to human/mouse dual agonists: a molecular modeling analysis.

Eli Lilly

O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.

Merck Research Laboratories

Discovery of cyclic amine-substituted benzoic acids as PPARa agonists.

Kyorin Pharmaceutical

Synthesis and pharmacological evaluation of novel benzoylazole-based PPARa/κ activators.

Dainippon Sumitomo Pharma

Development of a new class of benzoylpyrrole-based PPARa/¿ activators.

Dainippon Sumitomo Pharma

A stereo-controlled synthesis of 2,4-dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactone and its PPAR activities.

Seoul National University

Glycine amides as PPARalpha agonists.

Bayer-Schering Pharma

Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).

Bristol-Myers Squibb

Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators.

Glaxosmithkline

Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.

Merck Research Laboratories

Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma a

Merck Research Laboratories

Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.

F. Hoffmann-La Roche

The discovery of equipotent PPARalpha/gamma dual activators.

Glaxosmithkline

Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor alpha agonists.

Glaxosmithkline

Discovery and structure-activity relationship study of 2-piperazinyl-benzothiazole derivatives as potent and selective PPAR? agonists.

Shionogi

Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment.

Sichuan University

Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups--new classes of PPAR gamma/delta and PPAR alpha/gamma/delta agonists.

Bayer Pharmaceuticals

Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.

University of Tokyo

Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.

Novartis Institutes For Biomedical Research

Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.

Merck Research Laboratories

Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.

Università

Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.

Merck Research Laboratories

Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPAR?/? Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis.

China Pharmaceutical University

(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.

Merck Research Laboratories

Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.

Novo Nordisk

Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.

Ligand Pharmaceuticals

Discovery of novel modulators for the PPAR? (peroxisome proliferator activated receptor ?): Potential therapies for nonalcoholic fatty liver disease.

City of Hope National Medical Center

Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.

Kyorin Pharmaceutical

Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.

Glaxosmithkline

Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis.

Glaxosmithkline

Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis.

Glaxosmithkline

The PPARs: from orphan receptors to drug discovery.

Glaxo Wellcome Research & Development

A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.

Glaxo Wellcome Research & Development

Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPAR?)-selective agonists.

Okayama University

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.

Terns Pharmaceuticals

Discovery of potent and selective PPAR?/? dual antagonists and initial biological studies.

Inception Sciences

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.

Glaxo Wellcome Research and Development

In search of new herbicidal inhibitors of the non-mevalonate pathway.

Basf-Se

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR)?/?/? Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.

Inventiva

Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor?/? (PPAR?/?) dual agonists.

The University of Tokyo

Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist.

Bristol-Myers Squibb

Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.

Consiglio Nazionale Delle Ricerche